Abstract
Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.
Original language | English (US) |
---|---|
Pages (from-to) | 432-435 |
Number of pages | 4 |
Journal | Middle East African Journal of Ophthalmology |
Volume | 19 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2012 |
Externally published | Yes |
Keywords
- Benign Reactive Lymphoid Hyperplasia
- Rituximab
- Systemic
ASJC Scopus subject areas
- Ophthalmology